Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon hGH vs daily recombinant human growth hormone in pediatric growth hormone deficiency
CTR20200399Phase 3Completed
- Sponsor
- VISEN Pharmaceuticals
- Start
- Mar 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lonapegsomatropin in growth hormone deficiency (GHD), sponsored by VISEN Pharmaceuticals. Started Mar 2020; status: completed.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on CTR20200399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200399.